

Synthesis of strontium chondroitin sulfate and the evaluation of its capability to attenuate osteoarthritis



Ma F.B.^{a,1}, Liu N.^{a,1}, Hu N.^a, Wen C.Y.^b, Tang B.^{a,c,*}

^a Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, PR China

^b Interdisciplinary Division of Biomedical Engineering, Hong Kong Polytechnic University, HKUSAR, PR China

^c Shenzhen Key Laboratory of Nanoimprint Technology, Shenzhen, Guangdong, PR China

ARTICLE INFO

Article history:

Received 23 January 2017

Received in revised form 14 April 2017

Accepted 23 April 2017

Available online 27 April 2017

Keywords:

Chondroitin sulfate

Strontium

Cartilage

Osteoarthritis

ABSTRACT

Osteoarthritis (OA) is the most prevalent musculoskeletal disorder and the leading cause of joint disability in elderly patients. In this study, we fabricated strontium chondroitin sulfate (SrCS), a new polysaccharide-metal ion complex that is the combination of chondroitin sulfate and strontium, which are two widely adopted chemicals in OA clinical management. The structural, chemical compositions and morphology of as-fabricated SrCS were systematically investigated. Cell proliferation test, RT-PCR and preliminary animal studies were conducted to evaluate the clinical potential of SrCS on OA treatment. The materials characterization results verified that the Sr was successfully integrated into CS by replacing sodium in the original structure and formed a new polysaccharide-metal ion complex. The cell proliferation results indicated that the SrCS has excellent biocompatibility for both chondrocyte and osteoblast. The RT-PCR results showed that the SrCS can significantly increase the expression of COLII and ACAN, decrease MMP1 and MMP13 in chondrocyte and decrease the IL-6 and IL-1 β in both chondrocyte and osteoblast. Preliminary animal studies demonstrated that SrCS can effectively simulate the articular cartilage formation in SD-rats after modified Hulth's OA modeling surgery. We therefore believed that the SrCS should be a rather effective chemical for OA clinical management as well as a beneficial component for various biomaterials in cartilage tissue engineering.

© 2017 Elsevier Ltd. All rights reserved.

1. Introduction

Osteoarthritis (OA) is the joint disorders that generally characterized by articular cartilage (AC) degradation, subchondral bone sclerosis and osteophyte formation. It is prevalent worldwide and now is the leading cause of physical disability among aging adults (Clegg et al., 2006; Gutierrez et al., 2015; Wandel et al., 2010). There is no satisfactory clinical treatment for OA so far: pharmacological treatment of OA is limited to only relieve the symptom but fail to slow down the OA's progression, and total joint arthroplasty that might yield various complications is the final solution (Henrotin et al., 2001; Sharma, 2016). Although the etiology of OA is still unknown, it is generally accepted that the entire joint, including AC, subchondral plate and trabecular bone, are altered by OA and

the cross-talk between these joint tissues should be rather important in OA's pathology (Grover & Samson, 2016; Provenza et al., 2015; Xiao et al., 2016). Recent studies reported that the disequilibrium of bone metabolism will result in abnormal osteoid islets on subchondral bone, which is one of the critical steps in OA progression (Xiao et al., 2016; Zhen et al., 2013). Hence, both the AC and subchondral bone should be well considered for effective clinical treatment of OA.

Chondroitin sulfate (CS) is a complex, heterogeneous polysaccharide. It is the basic component of all connective tissues (Barnhill et al., 2006; du Souich, 2014; Ronca et al., 1998). Commercially available chondroitin sulfate extracted from cartilage generally exists in the form of sodium salt. The degree of sulfation and the chain length of extracted CS vary from different species and tissues, with the molecular weight range from 10 to 100 kDa (Tat, Pelletier, Mineau, Duval, & Martel-Pelletier, 2010). Chondroitin sulfate is anti-inflammatory, beneficial in collagen production and the anabolic/catabolic balance of chondrocytes (Ronca et al., 1998). Therefore, chondroitin sulfate currently is widely adopted on pharmacological treatment for OA, which was reported to be able to

* Corresponding author at: Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong, PR China.

E-mail address: tangbinsci@gmail.com (B. Tang).

¹ These authors contribute equally to this work.




Fig. 1. Synthesis pathway of SrCS (95% ethanol was applied to precipitate SrCS powder from SrCS liquid). The Sr^{2+} ions will substitute Na^+ ions and bond either $-\text{SO}_4^-$ or $-\text{COO}^-$ site (Cael, Winter, & Arnott, 1978).

effectively relieve the pain, improve the AC function and slow down the radiological progression of OA (Grover & Samson, 2016; Provenza et al., 2015; Roubille et al., 2015; Wandel et al., 2010; Zhang et al., 2008).

Strontium (Sr) is a trace element of human body that mainly exists in skeleton (Li et al., 2007). Sr is known as anti-inflammatory and antioxidant, and has been employed as antirheumatic drug for decades (Morandi, 1956). Strontium has beneficial effects on both bone and cartilage metabolism (Henrotin et al., 2001; Marie, 2006; Reinholt et al., 1985). Recent clinical studies suggested that Sr can reduce bone resorption, increase bone formation and simulate the formation of collagen matrix. Therefore, Sr has been gradually adopted in the OA treatment (Sharma, 2016; Wang et al., 2015; Wyland, 2015; Yu et al., 2013).

In this study, strontium chondroitin sulfate (SrCS), a new chemical combining chondroitin sulfate and strontium, was first fabricated through ion exchange method. We systematically investigated the chemical composition, structure and morphology of as-prepared SrCS and evaluated its potential capability on OA treatment. The results suggested that the proposed fabrication protocol can successfully integrate Sr into CS to form SrCS with high purity. Moreover, the SrCS is anti-inflammatory, rather effective in simulation collagen formation and helping the growth of cartilage. We therefore believed that SrCS fabricated in this work should be a promising chemical for various biomedical applications, especially those related to OA.

2. Materials and methods

2.1. Materials

The chondroitin sulfate used in this study was supplied by Henan Xingyuan Chemical products Co. Ltd., which is chondroitin sulfate A extracted from bovine trachea, with molecular weight 18 kDa (Supplementary Fig. 1). The cation exchange resin and strontium chloride used were purchased from Sinopharm Chemical Reagent Co., Ltd. Strontium hydroxide used in this study was purchased from Shanghai Chemical Reagent Co., China.

2.2. Synthesis of SrCS

Fig. 1 illustrates the synthesis pathway of SrCS. The fabrication process includes ion exchange, pH adjustment, CS-strontium chloride reaction and the SrCS precipitation. In the ion exchange procedure, a chromatographic column filled with pre-processed ion exchange resin (732 sodium cation resin) was employed to absorb sodium ions in CS. The CS (10 wt.%, 10 mL) solution was gradually added into the column with carefully controlled flow rate (1 mL/min) to ensure the maximum absorption. The output liquid that mainly contains chondroitin sulfate acid was collected using a clean beaker. With the purpose of improving the reaction conversion rate, pH adjustment was performed by adding suitable amount of strontium hydroxide to ensure the pH value of the collected liquid to be around 6.5. After that, strontium chloride solution was added into the pH-adjusted liquid to exchange residual sodium and




Fig. 2. (a) EDS spectra and the corresponding amount of elements (atomic weight percentage) in the final products fabricated with various amount of SrCl₂. (b) weight ratio of sodium/sulfur in raw material CS and strontium/sulfur in final product SrCS.




Fig. 3. Typical SEM image (a) CS, (b) SrCS and (c) XRD diffraction spectra of CS, SrCl₂, SrCS and CS&SrCl₂ mixture.




Fig. 4. FTIR spectra and ^1H NMR spectra (400 MHz, 298 K, D_2O) of strontium chondroitin sulfate (SrCS) and chondroitin sulfate (CS).

hydrogen ions, and formed SrCS. Finally, 95% ethanol was added into the mixture to precipitate SrCS. The collected precipitation was washed with 95% alcohol for at least three times to remove the possibly existed impurities. Before further experiments, the cleaned product was dried in a vacuum oven at 50°C for 24 h.

2.3. Materials characterization

The morphology of the fabricated product was examined using a TESCAN VEGA 3 LMH SEM (Zeiss, Germany). Gold sputtering was applied to enhance conductivity before SEM observation. The quantitative analysis of the strontium composition was conducted using the EDS integrated in the SEM. The crystal structure of the raw materials used for the fabrication and the final products were characterized using a D8 Advance ECO XRD (Bruker, Germany). The Fourier transform infrared (FTIR) spectra of CS and SrCS from 4000 cm^{-1} and 400 cm^{-1} were recorded in KBr at room temperature on a FTIR spectrophotometer Bruker vertex 70 (Bruker, Germany). The powder samples were mechanically pressed to be pellets before FTIR test. The *in vitro* stability of SrCS was investigated using the previous established protocol (Supplementary Fig. 2) (Hui, Zhang, Niu, Wang, & Sun, 2011).

^1H NMR was used to further explore the structure of the CS and the prepared SrCS. The ^1H NMR spectra were performed on a Bruker Avance III 400 with D_2O as the solvent. Mnova Software 9.0 (Mestrelab Research) integrated in the NMR was employed for spectral signal processing.

2.4. Cell proliferation test

The primary chondrocytes and osteoblasts were extracted from the articular cartilage disposal of an OA patient after total joint arthroplasty. The culture medium used for chondrocytes was HyClone medium containing DMEM (Dulbecco's Modified Eagle Medium) supplemented with 10% FBS (fetal bovine serum, Gemini). Human primary osteoblasts were maintained in DMEM/F12 (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12, GIBCO) with 10% FBS. Cells were incubated in an incubator at 37°C in 5% CO_2 .

The proliferation tests of OA chondrocytes and osteoblasts treated with various chemicals were performed with the Cell Counting kit-8 (DOJINDO) following the manufacturer's instruction. First, cells were seeded onto the 96well plate with identical density 4×10^4 cells/mL and incubated for 24 h before chemical treatment. After that, cells were treated with different concentrations of CS or SrCS and incubation for another 24 h. For proliferation assay, at each of the designated time points (1, 3 and 5 days), $10\ \mu\text{L}$

of CCK-8 solution was added to $100\ \mu\text{L}$ of culture medium and incubated for 2 h at 37°C . The absorbance of solution was measured using a microplate reader (Thermo, Multiskn Go) at 450 nm.

2.5. RT-PCR assay

Total RNA from cell and tissue samples were extracted with RNAiso plus following the instructions provided by the supplier. Total RNA samples were used to synthesize cDNA through reverse transcription kit (TAKARA). Briefly, a $10\ \mu\text{L}$ reaction including $0.5\ \mu\text{g}$ total RNA, reverse transcription was performed at 37°C for 15 min, and then terminated by heating at 85°C for 5 s.

RT products were performed in triplicate for microRNA or genes to be tested, using SYBR Green I. The PCR was processed at 95°C for 2 min, followed by 40 cycles of 95°C for 10 s and 60°C for 30 s. In addition, relative quantities (RQs) were measured with the comparative $2\Delta\Delta\text{CT}$ method. The primers used for gene detection were as follows:

F: 5'-AGATGAAGTGCTCCTCCAGG-3'	IL-1 β
R: 5'-TGGTCGGAGATTCTAGCTG-3'	IL-1 β
F: 5'-CTCAGCCCTGAGAAAGGAGA-3'	IL-6
R: 5'-TGATTTTCACCCAGGCAAGTCT-3'	IL-6
F: 5'-TAGAGGATGTGAGTGGTCTT-3'	ACAN
R: 5'-TCCACTAAGTACTGTCCAC-3'	ACAN
F: 5'-CCTCTGCCGACGACATAATCT-3'	COLII
R: 5'-CTCCTTTCTGTCCCTTGGT-3'	COLII
F: 5'-AGAAGGCTGGGCTCATT-3'	GAPDH
R: 5'-GGTGCTAAGCAGTTGGTGGT-3'	GAPDH

2.6. Animals and hematoxylineosin staining

The SD rats (male, 21 days old) were supplied by Guangdong Medical Laboratory Animal Center (Guangdong, China). The knee osteoarthritis was induced through modified Hulth's OA modeling method. In brief, rat's right knee was skin perpetrated, sterilized and made an inside-incision. After joint-space opening, anterior cruciate ligament transection (ACLT) was performed to cut off two-thirds of the medial meniscus. The control group was sham-operated. The postoperative rats were started to gavage with CS (1445 mg/kg), SrCS (1700 mg/kg) or vehicle for one month. The designed dose ensures that the amount of given chemical is the same for each group. All animal experiments were with the approval of the Animal Study Committee of Guangdong Medical Laboratory Animal Center.

In the hematoxylineosin staining experiment, knee joint tissues were firstly fixed in 4% paraformaldehyde for 24 h and decalcified in 15% EDTA solution at 4°C for 3 weeks for HE staining. The tissues were then processed for the standard dehydration, transparency and paraffin-embedding schedule. The paraffin blocks containing




Fig. 5. Cell viability of osteoblast (a–c) and chondrocyte (d–f) treated with SrCl₂, CS and SrCS at different concentrations. Data are presented as mean \pm S.D of the samples from three biological replicates at various treatment concentrations. *represents p value < 0.05, and *** represents p value < 0.001.

the cartilage tissues were cut at 4 μ m sections and stained with hematoxylin and eosin.

3. Results and discussion

3.1. Energy dispersive spectrometer (EDS)

We varied the weight percentage of SrCl₂ during the fabrication (0, 10, 20, 30, 40, 50, and 60% respectively) to adjust the amount of Sr in the final product. Fig. 2(a) shows the EDS results of the prod-

ucts yielded with various amount of SrCl₂. Significant peak of Na was detected in the final product without SrCl₂ (0% group), but for the final products fabricated with SrCl₂, the Na peaks disappeared. This suggested that the introduction of SrCl₂ enables the Na ions be exchanged completely. The atomic weight percentage of both Sr and Cl in the final product increased with the increasing amount of SrCl₂, which confirmed that the Sr content in the final product could be adjusted easily by controlling the addition of SrCl₂ during the fabrication. The small amount of Cl detected here should mainly be HCl residuals, which cannot be removed during precipi-




Fig. 6. Gene expression analysis of OA chondrocytes and osteoblasts after CS or SrCS treatment. Data are present as mean \pm S.D for three biological replicates. *represents p value < 0.05, ** represents p value < 0.01, and *** represents p value < 0.001.

tation process in current fabrication protocol. The theoretical value of Sr in SrCS is around 16%, if assume all the $-\text{SO}_4-$ or $-\text{COO}-$ sites are bonded with Sr. Thus the Cl detected in 50% and 60% group should be due to the existence of both HCl and SrCl_2 . Therefore, the SrCS for 40% group, which should have the highest amount of Sr but without SrCl_2 impurity, was used in materials characterization and biological experiments hereafter. It also can be further confirmed by the EDS results of weight ratio of strontium/sulfur in Fig. 2(b).

3.2. SEM and XRD

Fig. 3 is the typical SEM images of CS and SrCS. The morphology of SrCS and CS was found to be different: the CS was large particles with irregular shape and rough surface while the SrCS particles were rather small with round shape and smooth surface. Fig. 3(c) shows the XRD diffraction patterns of the raw materials: CS, SrCl_2 , the physical mixture of SrCl_2/CS and the as-prepared SrCS. There are no significant peaks on the XRD pattern of CS, while SrCl_2 diffraction patterns have certain significant peaks, which responses to its crystal orientations. The physically mixed SrCl_2/CS exhibits similar peaks as those of SrCl_2 . This confirmed that simply mixing the two stuffs will not change their crystal structures. The XRD result of SrCS exhibits no significant peaks, indicating its amorphous nature. The XRD characterization together with the EDS results confirmed that strontium ions were successfully introduced to the CS and formed a new complex.

3.3. The structure characterization of SrCS particles

Fig. 4(a) shows the FTIR spectra of the raw material CS and the final product SrCS. FTIR spectra significant absorption peak of CS and SrCS appeared at 3433 cm^{-1} (OH stretching), 2930 cm^{-1} (CH_2 stretching), 1642 cm^{-1} (amide I band), 1571 cm^{-1} (NH deformation), 1066 cm^{-1} (C–O stretching). Absorption peak 1257 cm^{-1} is asymmetric SO_2 stretching and 1127 cm^{-1} should be due to the symmetric SO_2 stretching. There are different types of CS, including chondroitin sulfate A, C–E. The characteristic adsorption peaks 928 cm^{-1} and 852 cm^{-1} found here belong to chondroitin sulfate A (Mathews, 1958). Blue shifts were found for SrCS FTIR spectra in absorption bands. For instance, peak 1414 cm^{-1} shifted to 1420 cm^{-1} and peak 1036 cm^{-1} shift to 1039 cm^{-1} . Na's electronegativity is slightly lower than that of Sr, and so the blue shifts found in the FTIR spectra should be the consequence of Sr–Na substitution. Comparing with the FTIR spectra for CS, peak intensity for SrCS spectrum increased remarkably, which indicates the formation of strong hydrogen bonding. FTIR spectra results therefore suggested that strontium has successfully bonded with CS molecule.

Representative ^1H NMR spectra of SrCS and CS samples are illustrated in Fig. 4(b) for the range 0–6 ppm. Certain characteristic signals in the ^1H NMR spectra related to SrCS and CS were observed. D_2O solvent peak can be seen in 4.5–4.80 ppm region. Result showed the presence of characteristic peaks CH (3.6 ppm) in SrCS and CS spectrum. Meanwhile, the signal 1.9 ppm can be readily assigned to the methyl protons (CH_3CO) in SrCS and CS. The ^1H NMR data of CS and SrCS shows resonances at 3.29 ppm and 3.48 ppm, characteristic H-2 and H-3 protons of the glucuronic acid (GlcA). Each spectrum has distinctive features but their respec-




Fig. 7. AC destruction in surgery-induced OA rat model after different treatment by CS or SrCS.

tive patterns are identical. This phenomenon indicated their similar position of protons in CS and SrCS. It is therefore believed that chondroitin sulfate and strontium ions were combined to form a polysaccharide-metal ion complex.

3.4. Cell proliferation test

Fig. 5 shows the cell viability of osteoblast and chondrocyte cultured with various concentrations of SrCl_2 , CS and SrCS respectively. The SrCl_2 significantly inhibited the proliferation of both osteoblast and chondrocyte with the increase of concentration. Although the cell viability of both osteoblast and chondrocyte treated by CS or SrCS at various concentrations does not have statistically significant variations, slight improvements on cell proliferation can be observed at certain concentrations. Therefore, we believed that the existence of CS and SrCS in the culture medium did not inhibit the cell proliferation, and the SrCS should be a safe chemical for clinical trial.

3.5. mRNA expression of cell examined using RT-PCR

Fig. 6 is the mRNA expression related to the cartilage formation (COLII, ACAN) and inflammation ($\text{IL1}\beta$ and IL6) of cells after different chemical treatments. We investigated the mRNA expression of collagen type II and aggrecan in human primary chondrocytes, which are the major components of cartilage and extracellular matrix. It is obvious that both COLII and ACAN mRNA expression levels see a remarkable increase after dealing with SrCS, while no significant enhancement of COLII and ACAN mRNA level can be observed in the chondrocytes after CS treatment (Fig. 6(a)–(b)). Conversely, the addition of SrCS or CS lead to a reduction of MMP1 and MMP13 (Fig. 6(e)–(f)), which are essential for cartilage degradation in OA.

SrCS was found to have significant anti-inflammatory effect. Fig. 6(c)–(d) shows the expression levels of $\text{IL1}\beta$ and IL6 of the chondrocytes, which are markedly reduced after SrCS treatment while increased by CS treatment. Similar results were found in osteoblasts treated with SrCS or CS (Fig. 6(g)–(h)). The strong anti-inflammatory effect of SrCS should be attributed to the existence of Sr, which is well-known anti-inflammatory and anti-oxidant




Fig. 8. Model of the effects of SrCS in attenuating the degradation of OA cartilage. The Sr in SrCS is anti-inflammation and can help in maintaining the bone metabolism and simulate collagen formation; the CS is also helpful in the collagen formation. Therefore, SrCS should be an effective chemical for OA treatment.

(Bruyere et al., 2008; Henrotin et al., 2001). Based on the Cell proliferation and RT-PCR results, it is believed that the SrCS should be a safe and rather effective chemical for OA clinical treatment.

3.6. SrCS or CS attenuates progression of OA in rats osteoarthritis model

To investigate whether SrCS can inhibit progression of osteoarthritis, we employed the rat surgery osteoarthritis model for preliminary *in vivo* study, and the histological results are shown in Fig. 7. It is clear that there were large extent of AC destruction for each group after surgery-induced osteoarthritis, but the vehicle treated rat cartilage thickness decreased the most, only 308 μm . Compared with vehicle-treated group, CS and SrCS treated rats cartilage increased to 397 μm and 480 μm respectively, indicating that both CS and SrCS may have beneficial effects for the recovery of AC suffering surgery-induced OA. Moreover, SrCS-treated rat cartilage significantly increased in non-surgery rat group compared to CS-treated rat, suggesting that SrCS may have a better impact on OA cartilage remodeling. The *in vivo* results thus indicate that the SrCS might be an effective drug for OA pathogenesis, and this is consistent with the previous *in vitro* results (Fig. 8).

4. Conclusions

In this study, SrCS, a new complex that is the combination of two effective chemicals (CS and Sr) in OA treatment was fabricated using ion exchange method. The material characterization of SrCS were performed using SEM, XRD, EDS, etc.; it was found that the CS was successfully integrated with Sr, and the amount of Sr in the final product can be well controlled by the amount of SrCl_2 adopted during the fabrication. The results of cell experiments showed that the fabricated SrCS is biological safe and effective in anti-inflammation. Moreover, it can effectively simulate the collagen formation and attenuate the degradation of OA AC. Preliminary animal study results agree with those found *in vitro*. Therefore, it is believed SrCS fabricated in this study should be a promising chemical in OA related biological applications.

Competing interests

The authors declare no competing financial interests.

Contributions

Tang B. and Wen C.Y. designed the work; Ma F.B. performed the materials related experiments, Liu N. and Hu N. performed the biological related experiments. All authors contributed to the data analysis. Ma F.B., Liu N., and Tang B. wrote the manuscript.

Acknowledgements

The authors would like to thank the financial support from Natural Science Foundation of China (Project No. 11202039), Guangdong Natural Science Foundation (No. 2015A030313792), Shenzhen Science and Technology Innovation Committee (Project Nos. JCYJ20120830154526544, JCYJ20140612140151890, ZDSYS20140509142721431).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.carbpol.2017.04.067>.

References

- Barnhill, J. G., Fye, C. L., Williams, D. W., Reda, D. J., Harris, C. L., & Clegg, D. O. (2006). Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial. *Journal of the American Pharmacists Association*, 46(1), 14–24.
- Bruyere, O., Delferriere, D., Roux, C., Wark, J. D., Spector, T., Devogelaer, J. P., et al. (2008). Effects of strontium ranelate on spinal osteoarthritis progression. *Annals of the Rheumatic Diseases*, 67(3), 335–339.
- Cael, J. J., Winter, W. T., & Arnott, S. (1978). Calcium chondroitin 4-SULFATE – Molecular-conformation and organization of polysaccharide chains in a proteoglycan. *Journal of Molecular Biology*, 125(1), 21–42.
- Clegg, D. O., Reda, D. J., Harris, C. L., Klein, M. A., O'Dell, J. R., Hooper, M. M., et al. (2006). Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *New England Journal of Medicine*, 354(8), 795–808.
- du Souich, P. (2014). Absorption, distribution and mechanism of action of SYSADOAS. *Pharmacology & Therapeutics*, 142(3), 362–374.

- Grover, A. K., & Samson, S. E. (2016). Benefits of antioxidant supplements for knee osteoarthritis: Rationale and reality. *Nutrition Journal*, 15.
- Gutierrez, M., Okano, T., Reginato, A. M., Cazenave, T., Ventura-Rios, L., Bertolazzi, C., et al. (2015). New ultrasound modalities in rheumatology. *JCR-Journal of Clinical Rheumatology*, 21(8), 427–434.
- Henrotin, Y., Labasse, A., Zheng, S. X., Galais, P., Tsouderos, Y., Crielaard, J. M., et al. (2001). Strontium ranelate increases cartilage matrix formation. *Journal of Bone and Mineral Research*, 16(2), 299–308.
- Hui, N., Zhang, W. L., Niu, X. L., Wang, Y., & Sun, W. (2011). Polarographic determination of chondroitin sulfate based on its interaction with crystal violet. *Latin American Applied Research*, 41(1), 95–98.
- Li, Z. Y., Lam, W. M., Yang, C., Xu, B., Ni, G. X., Abbah, S. A., et al. (2007). Chemical composition, crystal size and lattice structural changes after incorporation of strontium into biomimetic apatite. *Biomaterials*, 28(7), 1452–1460.
- Marie, P. J. (2006). Strontium ranelate: A dual mode of action rebalancing bone turnover in favour of bone formation. *Current Opinion in Rheumatology*, 18, S11–S15.
- Mathews, M. B. (1958). Isomeric chondroitin sulphates. *Nature*, 181(4606), 421–422.
- Morandi, G. A. (1956). Clinical experiments on an antirheumatic drug: 1-Ascorbo-alpha-phenylquinoline-gamma-carboxylic acid strontium salt. *Gazzetta Medica Italiana*, 115(9), 267–269.
- Provenza, J. R., Shinjo, S. K., Silva, J. M., Silva, G., Peron, C. R., & Castro Rocha, F. A. (2015). Combined glucosamine and chondroitin sulfate, once or three times daily, provides clinically relevant analgesia in knee osteoarthritis. *Clinical Rheumatology*, 34(8), 1455–1462.
- Reinholt, F. P., Engfeldt, B., Heinegard, D., & Hjerpe, A. (1985). Proteoglycans and glycosaminoglycans of normal and strontium rachitic epiphyseal cartilage. *Collagen and Related Research*, 5(1), 41–53.
- Ronca, F., Palmieri, L., Panicucci, P., & Ronca, G. (1998). Anti-inflammatory activity of chondroitin sulfate. *Osteoarthritis and Cartilage*, 6, 14–21.
- Roubille, C., Martel-Pelletier, J., Abram, F., Dorais, M., Delorme, P., Raynauld, J.-P., et al. (2015). Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: Data from the OAI progression cohort. *Seminars in Arthritis and Rheumatism*, 45(3), 257–267.
- Sharma, L. (2016). Osteoarthritis year in review 2015: Clinical. *Osteoarthritis and Cartilage*, 24(1), 36–48.
- Tat, S. K., Pelletier, J.-P., Mineau, F., Duval, N., & Martel-Pelletier, J. (2010). Variable effects of 3 different chondroitin sulfate compounds on human osteoarthritic cartilage/chondrocytes: Relevance of purity and production process. *Journal of Rheumatology*, 37(3), 656–664.
- Wandel, S., Jueni, P., Tendal, B., Nueesch, E., Villiger, P. M., Welton, N. J., et al. (2010). Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: Network meta-analysis. *British Medical Journal*, 341.
- Wang, K., Xu, J., Hunter, D. J., & Ding, C. (2015). Investigational drugs for the treatment of osteoarthritis. *Expert Opinion on Investigational Drugs*, 24(12), 1539–1556.
- Wyland, D. J. (2015). Subchondral calcium phosphate is ineffective for bone marrow edema lesions in adults with advanced osteoarthritis. *Clinical Orthopaedics and Related Research*, 473(12), 3976–3977.
- Xiao, Y.-P., Tian, F.-M., Dai, M.-W., Wang, W.-Y., Shao, L.-T., & Zhang, L. (2016). Are estrogen-related drugs new alternatives for the management of osteoarthritis? *Arthritis Research & Therapy*, 18.
- Yu, D., Ding, H., Mao, Y., Liu, M., Yu, B., Zhao, X., et al. (2013). Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model. *Acta Pharmacologica Sinica*, 34(3), 393–402.
- Zhang, W., Moskowitz, R. W., Nuki, G., Abramson, S., Altman, R. D., Arden, N., et al. (2008). OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis and Cartilage*, 16(2), 137–162.
- Zhen, G., Wen, C., Jia, X., Li, Y., Crane, J. L., Mears, S. C., et al. (2013). Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. *Nature Medicine*, 19(6), 704–+.